Der Internist

, 52:1047 | Cite as

Influenza

Klinische Symptome, Diagnostik und Therapie
Schwerpunkt

Zusammenfassung

Influenzainfektionen haben eine wesentliche sozioökonomische Bedeutung. Bislang waren v. a. kleine Kinder und ältere Erwachsene mit Begleiterkrankungen als Risikogruppen bekannt. In den letzten Jahren konnte neben der saisonalen Grippe das Auftreten der aviären Influenza im Jahr 2005 und einer neuen Pandemie mit dem nH1N1-Virus im Jahr 2009 beobachtet werden. Bei Letzterer sind andere Risikogruppen betroffen, und auch der klinische Verlauf ist unterschiedlich. Dieser Beitrag gibt einen aktuellen Überblick über die Epidemiologie, klinischen Symptome, Diagnostik und Therapie der Influenza.

Schlüsselwörter

Krankenhausaufenthalt Vogelgrippe Adamantan Neuraminidase Schutzimpfung 

Influenza

Clinical symptoms, diagnostics and therapy

Abstract

Influenza infections have important socio-economic consequences. Risk groups identified so far include small children and elderly adults with comorbidities. In recent years in addition to seasonal influenza an outbreak of avian influenza occurred in 2005 and the new H1N1 pandemic occurred in 2009. For the latter other at risk groups were affected and a different clinical course has been documented. The focus of this article is to give an overview on the epidemiology, clinical characteristics, diagnosis and therapy of influenza infections.

Keywords

Hospitalization Avian flu Adamantane Neuraminidase Vaccination 

Notes

Interessenkonflikt

Der Autor gibt an, dass kein Interessenkonflikt besteht.

Literatur

  1. 1.
    Robert Koch-Institut (2009) Bericht zur Epidemiologie der Influenza in Deutschland Saison 2009/10. http://influenza.rki.de/Saisonberichte/2009.pdf. Zugegriffen: 08.Juli 2011Google Scholar
  2. 2.
    Neuzil KM, Mellen BG, Wright PF et al (2000) The effect of influenza on hospitalizations, outpatient visits, and courses of antibiotics in children. N Engl J Med 342:225–231PubMedCrossRefGoogle Scholar
  3. 3.
    Thompson WW, Shay DK, Weintraub E et al (2004) Influenza-associated hospitalizations in the United States. JAMA 292:1333–1340PubMedCrossRefGoogle Scholar
  4. 4.
    Poland GA, Tosh P, Jacobson RM (2005) Requiring influenza vaccination for health care workers: seven truths we must accept. Vaccine 23:2251–2255PubMedCrossRefGoogle Scholar
  5. 5.
    Teichtahl H, Buckmaster N, Pertnikovs E (1997) The incidence of respiratory tract infection in adults requiring hospitalization for asthma. Chest 112:591–596PubMedCrossRefGoogle Scholar
  6. 6.
    Izurieta HS, Thompson WW, Kramarz P et al (2000) Influenza and the rates of hospitalization for respiratory disease among infants and young children. N Engl J Med 342:232–239PubMedCrossRefGoogle Scholar
  7. 7.
    Miller EK, Griffin MR, Edwards KM et al (2008) Influenza burden for children with asthma. Pediatrics 121:1–8PubMedCrossRefGoogle Scholar
  8. 8.
    Yap FH, Ho PL, Lam KF et al (2004) Excess hospital admissions for pneumonia, chronic obstructive pulmonary disease, and heart failure during influenza seasons in Hong Kong. J Med Virol 73:617–623PubMedCrossRefGoogle Scholar
  9. 9.
    Rohde G, Wiethege A, Borg I et al (2003) Respiratory viruses in exacerbations of chronic obstructive pulmonary disease requiring hospitalization – a case-control study. Thorax 58:37–42PubMedCrossRefGoogle Scholar
  10. 10.
    Webster RG, Govorkova EA (2006) H5N1 influenza – Continuing evolution and spread. N Engl J Med 355:2174–2177PubMedCrossRefGoogle Scholar
  11. 11.
    Sullivan SJ, Jacobson RM, Dowdle WR, Poland GA (2010) 2009 H1N1 influenza. Mayo Clin Proc 85:64–76PubMedCrossRefGoogle Scholar
  12. 12.
    World Health Organization (2011) Recommended composition of influenza virus vaccines for use in the 2011–2012 northern hemisphere influenza season. http://www.who.int/csr/disease/influenza/2011_02_recommendation.pdf. Zugegriffen: 08 Juli 2011Google Scholar
  13. 13.
    Modrow S, Falke D, Truyen U (2003) Molekulare Virologie. Spektrum Akademischer Verlag, HeidelbergGoogle Scholar
  14. 14.
    Rohde G (2010) Influenza A. Prevention and treatment. Hot Top Respir Med 5:23–29Google Scholar
  15. 15.
    Knipe DM, Howley PM, Griffin DE et al (2001) Field’s virology. Lippincott Williams & Wilkins, PhiladelphiaGoogle Scholar
  16. 16.
    Robert Koch Institut (2011) Influenza (Saisonale Influenza, Influenza A (H1N1) 2009, Aviäre Influenza) – RKI-Ratgeber für Ärzte. (updated 08.07.2011. http://www.rki.de/cln_153/nn_200120/DE/Content/Infekt/EpidBull/Merkblaetter/Ratgeber__Mbl__Influenza.html. Zugegriffen: 08 Juli 2011Google Scholar
  17. 17.
    Ferguson NM, Cummings DA, Cauchemez S et al (2005) Strategies for containing an emerging influenza pandemic in Southeast Asia. Nature 437:209–214PubMedCrossRefGoogle Scholar
  18. 18.
    Ott SR, Rohde G, Lepper PM et al (2010) The impact of viruses in lower respiratory tract infections of the adult. Part II: acute bronchitis, acute exacerbated COPD, pneumonia, and influenza. Pneumologie 64:18–27PubMedCrossRefGoogle Scholar
  19. 19.
    Riquelme R, Torres A, Rioseco ML et al (2011) Influenza pneumonia: a comparison between seasonal influenza virus and the H1N1 pandemic. Eur Respir J 38:106–111PubMedCrossRefGoogle Scholar
  20. 20.
    Dawood FS, Kamimoto L, D’Mello TA et al (2011) Children with asthma hospitalized with seasonal or pandemic influenza, 2003–2009. Pediatrics 128:e27–e32PubMedCrossRefGoogle Scholar
  21. 21.
    Pletz MW, Rohde G, Schutte H et al (2011) Epidemiologie und Erreger bei ambulant erworbener Pneumonie (CAP). Dtsch Med Wochenschr 136:775–780PubMedCrossRefGoogle Scholar
  22. 22.
    Tessmer A, Welte T, Schmidt-Ott R et al (2011) Influenza vaccination is associated with reduced severity of community-acquired pneumonia. Eur Respir J 38:147–153PubMedCrossRefGoogle Scholar
  23. 23.
    Rohde G, Drosten C, Borg I et al (2009) Detection of respiratory viruses – How, when, where and why? Pneumologie 63:14–22PubMedCrossRefGoogle Scholar
  24. 24.
    Lange W, Uphoff H (2002) Influenza-Diagnose: Zur Praktikabilität von Schnelltests. Dtsch Arztebl 99:2Google Scholar
  25. 25.
    Tabla VO de la, Antequera P, Masia M et al (2010) Clinical evaluation of rapid point-of-care testing for detection of novel influenza A (H1N1) virus in a population-based study in Spain. Clin Microbiol Infect 16:1358–1361PubMedCrossRefGoogle Scholar
  26. 26.
    Moscona A (2008) Medical management of influenza infection. Annu Rev Med 59:397–413PubMedCrossRefGoogle Scholar
  27. 27.
    Schmidt AC (2004) Antiviral therapy for influenza: a clinical and economic comparative review. Drugs 64:2031–2046PubMedCrossRefGoogle Scholar
  28. 28.
    Nicholson KG, Wood JM, Zambon M (2003) Influenza. Lancet 362:1733–1745PubMedCrossRefGoogle Scholar
  29. 29.
    Jefferson T, Demicheli V, Rivetti D et al (2006) Antivirals for influenza in healthy adults: systematic review. Lancet 367:303–313PubMedCrossRefGoogle Scholar
  30. 30.
    Laplante JM, Marshall SA, Shudt M et al (2009) Influenza antiviral resistance testing in New York and Wisconsin, 2006–2008: methodology and surveillance data. J Clin Microbiol 47:1372–1378PubMedCrossRefGoogle Scholar
  31. 31.
    Bright RA, Medina MJ, Xu X et al (2005) Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994–2005: a cause for concern. Lancet 366:1175–1181PubMedCrossRefGoogle Scholar
  32. 32.
    Bright RA, Shay DK, Shu B et al (2006) Adamantane resistance among influenza A viruses isolated early during the 2005–2006 influenza season in the United States. JAMA 295:891–894PubMedCrossRefGoogle Scholar
  33. 33.
    Buranathai C, Amonsin A, Chaisigh A et al (2007) Surveillance activities and molecular analysis of H5N1 highly pathogenic avian influenza viruses from Thailand, 2004–2005. Avian Dis 51:194–200PubMedCrossRefGoogle Scholar
  34. 34.
    Cheung CL, Rayner JM, Smith GJ et al (2006) Distribution of amantadine-resistant H5N1 avian influenza variants in Asia. J Infect Dis 193:1626–1629PubMedCrossRefGoogle Scholar
  35. 35.
    He G, Qiao J, Dong C et al (2008) Amantadine-resistance among H5N1 avian influenza viruses isolated in Northern China. Antiviral Res 77:72–76PubMedCrossRefGoogle Scholar
  36. 36.
    Schunemann HJ, Hill SR, Kakad M et al (2007) WHO rapid advice guidelines for pharmacological management of sporadic human infection with avian influenza A (H5N1) virus. Lancet Infect Dis 7:21–31PubMedCrossRefGoogle Scholar
  37. 37.
    Okomo-Adhiambo M, Nguyen HT, Sleeman K et al (2009) Host cell selection of influenza neuraminidase variants: implications for drug resistance monitoring in A (H1N1) viruses. Antiviral Res 85:381–388PubMedCrossRefGoogle Scholar
  38. 38.
    Sheu TG, Fry AM, Garten RJ et al (2011) Dual resistance to adamantanes and oseltamivir among seasonal influenza A (H1N1) viruses: 2008–2010. J Infect Dis 203:13–17PubMedCrossRefGoogle Scholar
  39. 39.
    Moscona A (2005) Neuraminidase inhibitors for influenza. N Engl J Med 353:1363–1373PubMedCrossRefGoogle Scholar
  40. 40.
    Stiver G (2003) The treatment of influenza with antiviral drugs. CMAJ 168:49–56PubMedGoogle Scholar
  41. 41.
    Ruf BR, Szucs T (2009) Reducing the burden of influenza-associated complications with antiviral therapy. Infection 37:186–196PubMedGoogle Scholar
  42. 42.
    Hedrick JA, Barzilai A, Behre U et al (2000) Zanamivir for treatment of symptomatic influenza A and B infection in children five to twelve years of age: a randomized controlled trial. Pediatr Infect Dis J 19:410–417PubMedCrossRefGoogle Scholar
  43. 43.
    Hayden FG, Osterhaus AD, Treanor JJ et al (1997) Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections. GG167 Influenza Study Group. N Engl J Med 337:874–880PubMedCrossRefGoogle Scholar
  44. 44.
    Management of Influenza in the Southern Hemisphere Trialists (MIST) Study Group (1998) Randomised trial of efficacy and safety of inhaled zanamivir in treatment of influenza A and B virus infections. Lancet 352:1877–1881CrossRefGoogle Scholar
  45. 45.
    Whitley RJ, Hayden FG, Reisinger KS et al (2001) Oral oseltamivir treatment of influenza in children. Pediatr Infect Dis J 20:127–133PubMedCrossRefGoogle Scholar
  46. 46.
    Treanor JJ, Hayden FG, Vrooman PS et al (2000) Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. JAMA 283:1016–1024PubMedCrossRefGoogle Scholar
  47. 47.
    Peters PH Jr, Gravenstein S, Norwood P et al (2001) Long-term use of oseltamivir for the prophylaxis of influenza in a vaccinated frail older population. J Am Geriatr Soc 49:1025–1031PubMedCrossRefGoogle Scholar
  48. 48.
    Godlee F, Clarke M (2009) Why don’t we have all the evidence on oseltamivir? BMJ 339:b5351PubMedCrossRefGoogle Scholar
  49. 49.
    Jefferson T, Jones M, Doshi P, Del Mar C (2009) Neuraminidase inhibitors for preventing and treating influenza in healthy adults: systematic review and meta-analysis. BMJ 339:b5106PubMedCrossRefGoogle Scholar
  50. 50.
    Kaiser L, Wat C, Mills T, Mahoney P et al (2003) Impact of oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalizations. Arch Intern Med 163:1667–1672PubMedCrossRefGoogle Scholar
  51. 51.
    Doshi P (2009) Neuraminidase inhibitors – the story behind the Cochrane review. BMJ 339:b5164PubMedCrossRefGoogle Scholar
  52. 52.
    Jefferson T, Jones M, Doshi P et al (2010) Neuraminidase inhibitors for preventing and treating influenza in healthy adults. Cochrane Database Syst Rev 2:CD001265PubMedGoogle Scholar
  53. 53.
    Kiso M, Mitamura K, Sakai-Tagawa Y et al (2004) Resistant influenza A viruses in children treated with oseltamivir: descriptive study. Lancet 364:759–765PubMedCrossRefGoogle Scholar
  54. 54.
    Correia V, Andrade HR, Santos LA et al (2010) Antiviral drug profile of seasonal influenza viruses circulating in Portugal from 2004/2005–2008/2009 winter seasons. Antiviral Res 86:128–136PubMedCrossRefGoogle Scholar
  55. 55.
    Lackenby A, Hungnes O, Dudman SG et al (2008) Emergence of resistance to oseltamivir among influenza A(H1N1) viruses in Europe. Euro Surveill 13:pii 8026PubMedGoogle Scholar
  56. 56.
    Thorlund K, Awad T, Boivin G, Thabane L (2011) Systematic review of influenza resistance to the neuraminidase inhibitors. BMC Infect Dis 11:134PubMedCrossRefGoogle Scholar
  57. 57.
    Moscona A (2009) Global transmission of oseltamivir-resistant influenza. N Engl J Med 360:953–956PubMedCrossRefGoogle Scholar
  58. 58.
    Hurt AC, Holien JK, Parker M et al (2009) Zanamivir-resistant influenza viruses with a novel neuraminidase mutation. J Virol 83:10366–10373PubMedCrossRefGoogle Scholar
  59. 59.
    Medeiros R, Rameix-Welti MA, Lorin V et al (2007) Failure of zanamivir therapy for pneumonia in a bone-marrow transplant recipient infected by a zanamivir-sensitive influenza A (H1N1) virus. Antivir Ther 12:571–576PubMedGoogle Scholar
  60. 60.
    Ellebedy AH, Webby RJ (2009) Influenza vaccines. Vaccine 27(Suppl 4):D65–D68PubMedCrossRefGoogle Scholar
  61. 61.
    Jefferson T, Di Pietrantonj C, Rivetti A et al (2010) Vaccines for preventing influenza in healthy adults. Cochrane Database Syst Rev 7:CD001269PubMedGoogle Scholar
  62. 62.
    Sambhara S, McElhaney JE (2009) Immunosenescence and influenza vaccine efficacy. Curr Top Microbiol Immunol 333:413–429PubMedCrossRefGoogle Scholar
  63. 63.
    Groenwold RH, Hoes AW, Hak E (2009) Impact of influenza vaccination on mortality risk among the elderly. Eur Respir J 341:56–62CrossRefGoogle Scholar
  64. 64.
    Schembri S, Morant S, Winter JH, MacDonald TM (2009) Influenza but not pneumococcal vaccination protects against all-cause mortality in patients with COPD. Thorax 647:567–572CrossRefGoogle Scholar
  65. 65.
    Poole P, Chacko E, Wood-Baker R, Cates C (2006) Influenza vaccine for patients with chronic obstructive pulmonary disease. Cochrane Database Syst Rev 1:CD002733PubMedGoogle Scholar
  66. 66.
    Cates CJ, Jefferson TO, Rowe BH (2008) Vaccines for preventing influenza in people with asthma. Cochrane Database Syst Rev 2:CD000364PubMedGoogle Scholar
  67. 67.
    Pesek R, Lockey R (2011) Vaccination of adults with asthma and COPD. Allergy 661:25–31CrossRefGoogle Scholar
  68. 68.
    CDC (2009) Safety of influenza A (H1N1) 2009 monovalent vaccines – United States, October 1-November 24, 2009. MMWR Morb Mortal Wkly Rep 58:1351–1356Google Scholar

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  1. 1.Department of Respiratory MedicineUniversity Medical Center MaastrichtMaastrichtNetherlands

Personalised recommendations